{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:02:55Z","timestamp":1766023375576,"version":"3.48.0"},"reference-count":32,"publisher":"e-Century Publishing Corporation","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Blood Res"],"DOI":"10.62347\/jmfo7582","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T03:47:14Z","timestamp":1730346434000},"page":"14-21","source":"Crossref","is-referenced-by-count":0,"title":["Heparin-induced thrombocytopenia-II in hospitalized patients with surgery or deep vein thrombosis"],"prefix":"10.62347","volume":"14","author":[{"given":"Narges","family":"Gomar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1076029620962857","DOI":"10.1177\/1076029620962857","article-title":"Prediction of heparin induced thrombocytopenia (HIT) using a combination of 4Ts score and screening immune assays","volume":"26","author":"Thawani","year":"2020","unstructured":"Thawani R, Nannapaneni S, Kumar V, Oo P, Simon M, Huang A, Malhotra I and Xu Y. Prediction of heparin induced thrombocytopenia (HIT) using a combination of 4Ts score and screening immune assays. Clin Appl Thromb Hemost 2020; 26: 1076029620962857.","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref1","unstructured":"Nicolas D, Nicolas S, Hodgens A and Reed M. Heparin-Induced Thrombocytopenia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/1358863X19898253","article-title":"Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management","volume":"25","author":"Hogan","year":"2020","unstructured":"Hogan M and Berger JS. Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management. Vasc Med 2020; 25: 160-173.","journal-title":"Vasc Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/pgmj.2007.059188","article-title":"Heparin induced thrombocytopenia: diagnosis and management update","volume":"83","author":"Ahmed","year":"2007","unstructured":"Ahmed I, Majeed A and Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J 2007; 83: 575-582.","journal-title":"Postgrad Med J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.athoracsur.2003.09.034","article-title":"Heparin-induced thrombocytopenia and cardiac surgery","volume":"76","author":"Warkentin","year":"2003","unstructured":"Warkentin TE and Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003; 76: 2121-2131.","journal-title":"Ann Thorac Surg"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S and Crowther M. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 Suppl: e495S-e530S.","DOI":"10.1378\/chest.11-2303"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/ATVBAHA.120.315445","article-title":"Heparin-induced thrombocytopenia: a focus on thrombosis","volume":"41","author":"Arepally","year":"2021","unstructured":"Arepally GM and Padmanabhan A. Heparin-induced thrombocytopenia: a focus on thrombosis. Arterioscler Thromb Vasc Biol 2021; 41: 141-152.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Levi M and Opal SM. Coagulation abnormalities in critically ill patients. Surgical Intensive Care Medicine 2016; 463-471.","DOI":"10.1007\/978-3-319-19668-8_34"},{"key":"ref8","unstructured":"Ahmadinejad M, Shahbazi M, Chegini A, Shamriz R and Ahmadinejad Z. Prevalence of heparin induced thrombocytopenia among iranian patients with cardiac surgery. Res Pract Thromb Haemost 2011; 1: 1366-1367."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12959-023-00546-8","article-title":"How to assess hypercoagulability in heparin-induced thrombocytopenia? Biomarkers of potential value to support therapeutic intensity of non-heparin anticoagulation","volume":"21","author":"Barocas","year":"2023","unstructured":"Barocas A, Savard P, Carlo A, Lecompte T and de Maistre E. How to assess hypercoagulability in heparin-induced thrombocytopenia? Biomarkers of potential value to support therapeutic intensity of non-heparin anticoagulation. Thromb J 2023; 21: 100.","journal-title":"Thromb J"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Liu X, Zhang X, Xiao Y, Gao T, Wang G, Wang Z, Zhang Z, Hu Y, Dong Q and Zhao S. Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment. MedRxiv 2020; 2020.2004. 2023.20076851.","DOI":"10.1101\/2020.04.23.20076851"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev.med.042808.171814","article-title":"Heparin-induced thrombocytopenia","volume":"61","author":"Arepally","year":"2010","unstructured":"Arepally GM and Ortel TL. Heparin-induced thrombocytopenia. Annu Rev Med 2010; 61: 77-90.","journal-title":"Annu Rev Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12885-023-10665-0","article-title":"MicroRNA-125b as a valuable predictive marker for outcome after autologous hematopoietic stem cell transplantation","volume":"23","author":"Rafiee","year":"2023","unstructured":"Rafiee M, Amiri F, Mohammadi MH and Hajifathali A. MicroRNA-125b as a valuable predictive marker for outcome after autologous hematopoietic stem cell transplantation. BMC Cancer 2023; 23: 202.","journal-title":"BMC Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3390\/jcm10040683","article-title":"Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management","volume":"10","author":"Marchetti","year":"2021","unstructured":"Marchetti M, Zermatten MG, Bertaggia Calderara D, Aliotta A and Alberio L. Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management. J Clin Med 2021; 10: 683.","journal-title":"J Clin Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.18502\/ijhoscr.v15i4.7478","article-title":"Heparin-induced thrombocytopenia in iranian cardiac surgery patients using the 4Ts clinical scoring system and laboratory methods","volume":"15","author":"Ahmadinejad","year":"2021","unstructured":"Ahmadinejad M, Shahbazi M and Chegini A. Heparin-induced thrombocytopenia in iranian cardiac surgery patients using the 4Ts clinical scoring system and laboratory methods. Int J Hematol Oncol Stem Cell Res 2021; 15: 230-238.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1001\/archinternmed.2007.65","article-title":"Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy","volume":"168","author":"GB","year":"2008","unstructured":"Oliveira GB, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, Moliterno DJ, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Ohman EM and Granger CB; Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry Investigators. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008; 168: 94-102.","journal-title":"Arch Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jvsv.2023.02.001","article-title":"Prevalence and outcomes of heparin-induced thrombocytopenia in hospitalized patients with venous thromboembolic disease: insight from national inpatient sample","volume":"11","author":"Shah","year":"2023","unstructured":"Shah NB, Sharedalal P, Shafi I, Tang A, Zhao H, Lakhter V, Kolluri R, Rao AK and Bashir R. Prevalence and outcomes of heparin-induced thrombocytopenia in hospitalized patients with venous thromboembolic disease: insight from national inpatient sample. J Vasc Surg Venous Lymphat Disord 2023; 11: 723-730.","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Dhakal B, Kreuziger LB, Rein L, Kleman A, Fraser R, Aster RH, Hari P and Padmanabhan A. Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. Lancet Haematol 2018; 5: e220-e231.","DOI":"10.1016\/S2352-3026(18)30046-2"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/j.jacc.2016.02.073","article-title":"Heparin-induced thrombocytopenia: a comprehensive clinical review","volume":"67","author":"Salter","year":"2016","unstructured":"Salter BS, Weiner MM, Trinh MA, Heller J, Evans AS, Adams DH and Fischer GW. Heparin-induced thrombocytopenia: a comprehensive clinical review. J Am Coll Cardiol 2016; 67: 2519-2532.","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Patriarcheas V, Pikoulas A, Kostis M, Charpidou A and Dimakakos E. Heparin-induced thrombocytopenia: pathophysiology, diagnosis and management. Cureus 2020; 12: e7385.","DOI":"10.7759\/cureus.7385"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","article-title":"Temporal aspects of heparin-induced thrombocytopenia","volume":"344","author":"Warkentin","year":"2001","unstructured":"Warkentin TE and Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292.","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s11239-017-1478-0","article-title":"Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study","volume":"43","author":"Mantha","year":"2017","unstructured":"Mantha S, Miao Y, Wills J, Parameswaran R and Soff GA. Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. J Thromb Thrombolysis 2017; 43: 514-518.","journal-title":"J Thromb Thrombolysis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/jcph.1635","article-title":"Rivaroxaban as an alternative agent for heparin-induced thrombocytopenia","volume":"60","author":"Farasatinasab","year":"2020","unstructured":"Farasatinasab M, Zarei B, Moghtadaei M, Nasiripour S, Ansarinejad N and Zarei M. Rivaroxaban as an alternative agent for heparin-induced thrombocytopenia. J Clin Pharmacol 2020; 60: 1362-1366.","journal-title":"J Clin Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3171\/2008.3.17480","article-title":"The incidence of heparin-induced thrombocytopenia type II in patients with subarachnoid hemorrhage treated with heparin versus enoxaparin","volume":"110","author":"Kim","year":"2009","unstructured":"Kim GH, Hahn DK, Kellner CP, Komotar RJ, Starke R, Garrett MC, Yao J, Cleveland J, Mayer SA and Connolly ES. The incidence of heparin-induced thrombocytopenia type II in patients with subarachnoid hemorrhage treated with heparin versus enoxaparin. J Neurosurg 2009; 110: 50-57.","journal-title":"J Neurosurg"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tmrv.2019.08.001","article-title":"The use of flow cytometry in the diagnosis of heparin-induced thrombocytopenia (HIT)","volume":"34","author":"Mali&#x10D","year":"2020","unstructured":"Maličev E. The use of flow cytometry in the diagnosis of heparin-induced thrombocytopenia (HIT). Transfus Med Rev 2020; 34: 34-41.","journal-title":"Transfus Med Rev"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.3892\/mmr.2019.10484","article-title":"Extraction and identification of platelet-derived microparticles","volume":"20","author":"Guo","year":"2019","unstructured":"Guo J, Feng C, Zhang B, Zhang S, Shen X, Zhu J and Zhao XX. Extraction and identification of platelet-derived microparticles. Mol Med Rep 2019; 20: 2916-2921.","journal-title":"Mol Med Rep"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Campello E, Radu CM, Duner E, Lombardi AM, Spiezia L, Bendo R, Ferrari S, Simioni P and Fabris F. Activated platelet-derived and leukocyte-derived circulating microparticles and the risk of thrombosis in heparin-induced thrombocytopenia: a role for PF4-bearing microparticles? Cytometry B Clin Cytom 2018; 94: 334-341.","DOI":"10.1002\/cyto.b.21507"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jamcollsurg.2004.02.027","article-title":"P-selectin and antibodies against heparin-platelet factor 4 in patients with venous or arterial diseases after a 7-day heparin treatment","volume":"199","author":"Papalambros","year":"2004","unstructured":"Papalambros E, Sigala F, Travlou A, Bastounis E and Mirilas P. P-selectin and antibodies against heparin-platelet factor 4 in patients with venous or arterial diseases after a 7-day heparin treatment. J Am Coll Surg 2004; 199: 69-77.","journal-title":"J Am Coll Surg"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/107602960000600204","article-title":"Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders","volume":"6","author":"Amin","year":"2000","unstructured":"Amin HM, Ahmad S, Walenga JM, Hoppensteadt DA, Leitz H and Fareed J. Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders. Clin Appl Thromb Hemost 2000; 6: 71-76.","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s00380-010-0111-3","article-title":"In patients with idiopathic venous thrombosis, interleukin-10 is decreased and related to endothelial dysfunction","volume":"26","author":"Poredos","year":"2011","unstructured":"Poredos P and Jezovnik MK. In patients with idiopathic venous thrombosis, interleukin-10 is decreased and related to endothelial dysfunction. Heart Vessels 2011; 26: 596-602.","journal-title":"Heart Vessels"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/ATVBAHA.119.313137","article-title":"IL (Interleukin)-6 contributes to deep vein thrombosis and is negatively regulated by miR-338-5p","volume":"40","author":"Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z, Wei R, Miao X, Sun S, Liang G, Chu C, Zhao L, Zhu X, Guo Q, Wang B and Li X. IL (Interleukin)-6 contributes to deep vein thrombosis and is negatively regulated by miR-338-5p. Arterioscler Thromb Vasc Biol 2020; 40: 323-334.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4081\/oncol.2019.413","article-title":"Thrombocytopenia in solid tumors: prognostic significance","volume":"13","author":"Ghanavat","year":"2019","unstructured":"Ghanavat M, Ebrahimi M, Rafieemehr H, Maniati M, Behzad MM and Shahrabi S. Thrombocytopenia in solid tumors: prognostic significance. Oncol Rev 2019; 13: 413.","journal-title":"Oncol Rev"}],"container-title":["American Journal of Blood Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajbr\/14\/3\/ajbr0159408.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:59Z","timestamp":1766023079000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajbr\/14\/3\/ajbr0159408.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/jmfo7582","relation":{},"ISSN":["2160-1992"],"issn-type":[{"type":"electronic","value":"2160-1992"}],"subject":[],"published":{"date-parts":[[2024]]}}}